3SBio Inc. (FRA:83B)

Market Cap	4.78B -41.1%
Revenue (ttm)	2.30B +96.9%
Net Income	1.07B +250.7%
EPS	0.42 +238.8%
Shares Out	n/a
PE Ratio	4.48
Forward PE	12.56
Dividend	0.03 (1.47%)
Ex-Dividend Date	Jul 21, 2026

Volume	n/a
Open	1.876
Previous Close	1.878
Day's Range	1.876 - 1.876
52-Week Range	1.634 - 3.880
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 20, 2026

About 3SBio

3SBio Inc., an investment holding company, engages in the development, production, marketing, and sale of biopharmaceutical products in the People’s Republic of China, the United States, and internationally. The company offers TPIAO bio-pharmaceutical drug for the treatment of chemotherapy-induced thrombocytopenia, immune thrombocytopenia, pediatric ITP, and chronic liver disease-related thrombocytopenia. It also provides EPIAO for indications, such as the treatment of anemia associated with chronic kidney disease, chemotherapy-induced anemia, ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1993
• Employees: 6,068
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 83B

Financial Performance

In 2025, 3SBio's revenue was 17.70 billion, an increase of 94.29% compared to the previous year's 9.11 billion. Earnings were 8.48 billion, an increase of 305.78%.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 26, 2026

Data Sources Report a data error